Autism Spectrum Disorder Therapeutics Market by Distribution Channel, Type, and Geography - Forecast and Analysis 2023-2027

Published: Oct 2023

Pages: 157

SKU: IRTNTR75331

Snapshot

Autism Spectrum Disorder Therapeutics Market Forecast 2023-2027

The autism spectrum disorder therapeutics market size is forecast to increase by USD 772.65 million, at a CAGR of 7.2% between 2022 and 2027. The market's expansion relies on numerous factors, notably the rising incidence of autism spectrum disorder, the proliferation of public-private partnerships, and the increasing awareness surrounding it. As the prevalence of autism spectrum disorder continues to increase globally, there is a growing demand for related products, services, and interventions to support affected individuals and their families. Additionally, the formation of public-private partnerships facilitates collaboration between government agencies, healthcare providers, and private entities to address the complex needs of individuals with ASD more effectively. Furthermore, heightened awareness campaigns and educational initiatives contribute to greater recognition and understanding of ASD within society, driving the demand for related resources and solutions. Our analysis encompasses these pivotal factors, offering insights into the market dynamics and opportunities for growth.

What will be the size of the Market During the Forecast Period?

To learn more about this report, View Report Sample

Market Segmentation

In the realm of the market, addressing the diverse needs of patients across pediatric patients and adult patient populations is paramount. Behavioral therapies play a central role in managing symptoms, especially considering the communication challenges often associated with ASD. With a focus on understanding the underlying genetic condition, efforts aim to improve the diagnosis rate and reduce the age of diagnosis to ensure timely intervention. Collaboration between hospital pharmacy segment and drug stores facilitates access to essential medications for individuals with autism spectrum disorder.

Further, this market report extensively covers market segmentation by distribution channel (retail pharmacy, hospital pharmacy, and online pharmacy), type (stimulants, selective serotonin reuptake inhibitors, antipsychotic drugs, sleep medications, and others), and geography (North America, Europe, Asia, and Rest of World). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.

By Distribution Channel

The market share by the retail pharmacy segment will be significant during the forecast period. There is no cure for ASD, although there are several therapies and drugs available to help manage the symptoms. The market is expected to grow at a rapid pace over the next few years due to the growing awareness and prevalence of the condition and breakthroughs in novel treatment options. Retail pharmacies are the most accessible and convenient source of medications for patients with ASD.

Get a glance at the market contribution of various segments View the PDF Sample

The retail pharmacy segment was valued at USD 841.83 million in 2017. The rising prevalence of autism spectrum disorder has increased the demand for medicines and other treatments. Secondly, the growing awareness about the disorder has resulted in more patients seeking treatment and medication options. Finally, the global expansion of retail pharmacies as well as the availability of online pharmacies has made it easier for people to obtain therapeutic drugs. As more effective treatment choices become available, the demand for drugs and other therapies is expected to increase, and retail pharmacies will play an important role in ensuring that these options are available. Thus, the retail pharmacy segment is expected to drive the growth of the market during the forecast period.

By Region

For more insights on the market share of various regions Download PDF Sample now!

North America is estimated to contribute 39% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. The high prevalence of ASD in the region, rising awareness of the illness, and the availability of advanced treatment options are driving the growth of the market in North America. Because of their widespread presence and the convenience that they offer to patients with ASD, retail pharmacies are the most popular distribution channel in North America. However, due to the availability of modern pharmaceuticals and specialized services, hospital pharmacies and specialty pharmacies are also growing in popularity.

Market Dynamics Customer Landscape

The market is witnessing notable advancements in personalized therapies aimed at addressing the unique needs of patients across all age groups, from pediatric to adult. Pharmaceutical companies are developing innovative therapies to manage symptoms such as aggressive behaviors and mood stabilization associated with ASD. Early diagnosis is crucial, given the challenges in communication and the varying diagnosis rates. With a focus on addressing genetic conditions and disorders like autistic disorder, Asperger's syndrome, and Pervasive Development Disorder (PDD), the market strives to improve the quality of life for individuals with ASD across the globe. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Market Driver

The increasing prevalence of ASD is notably driving the market growth. ASD is a complicated neurodevelopmental illness that affects communication and social interaction abilities as well as the behavior of those diagnosed with it. The disorder is characterized by a variety of symptoms, the severity of which varies from person to person. According to the Center for Disease Control and Prevention (CDC), roughly one in every 54 children in the US has ASD, representing a ten-fold increase in the prevalence of ASD over the past four decades.

Similarly, the World Health Organization (WHO) estimates that one out of every 160 children worldwide has ASD. As the number of individuals who have increased, there is a greater need for suitable therapy alternatives that can assist in controlling the symptoms of the disorder. Further, there is a growing need for drugs and other therapies that can help in managing the symptoms of ASD. Thus, the increasing prevalence is expected to drive the growth of the market during the forecast period.

Key Market Trends

The increasing interest in personalized medicine is the key trend shaping the market. Personalized medicine procedures for the treatment of ASD are gaining popularity. Personalized medicine is the practice of personalized medical treatments to individual patients based on their genetic, environmental, and lifestyle characteristics. The aim is to provide a more accurate and effective treatment with fewer adverse effects. ASD is a complex condition with diverse symptoms and severity among people. Because of this heterogeneity, developing effective medications that work for all individuals is difficult. Personalized medicine approaches ASD therapy try to solve this issue by providing individualized treatment programs based on the specific needs of each patient.

Furthermore, some studies have discovered that mutations in the SHANK3 gene are linked to a severe form of ASD, and researchers are looking at new treatments that could target this gene. Another area of study is the use of biomarkers to identify specific ASD subtypes and develop tailored treatments. Researchers are looking into a variety of biomarkers such as brain imaging, gene expression, and metabolic indicators to discover ASD subtypes that can respond differently to different treatments. Thus, the increasing interest in personalized medicine for the treatment of ASD is one of the major trends that will drive the growth of the market during the forecast period.

Major Market Challenge

Stringent regulations may impede market growth. Regulatory agencies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) play an important role in guaranteeing the safety and efficacy of drugs and other therapies used in the treatment of ASD patients. While antipsychotics have been demonstrated to be beneficial in controlling some of the behavioral symptoms associated with ASD, they are also associated with substantial adverse effects, including weight gain, metabolic abnormalities, and difficulties in mobility.

Additionally, ASD therapies include those that treat the wide variations in both the symptoms as well as the severity of the condition among people with ASD. This diversity in symptoms can make it difficult to create clear regulatory clearance standards and may lead to a lack of clarity among healthcare practitioners about the optimal treatment techniques. Thus, the stringent regulations on ASD therapeutics and treatments will hinder the growth of the market during the forecast period.

Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Market Customer Landscape

Who are the Major Market Players?

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Bristol Myers Squibb Co. - The company offers autism spectrum disorder therapeutics such as aripiprazole.

The research report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Segment Overview

The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.

Distribution Channel
- Retail pharmacy
- Hospital pharmacy
- Online pharmacy

Type
- Stimulants
- Selective serotonin reuptake inhibitors
- Antipsychotic drugs
- Sleep medications
- Others

Geography
- North America
  - The U.S.
  - Canada
- Europe
  - U.K.
  - Germany
  - France
  - Rest of Europe
- Asia
  - China
  - India
- ROW
  - Australia
  - Brazil
  - Saudi Arabia

Market Analyst Overview

In the realm of autism spectrum disorder (ASD) therapeutics, addressing the diverse needs of patients across pediatric and adult populations is paramount. Behavioral therapies play a central role in managing symptoms, especially considering the communication challenges often associated with ASD. With a focus on understanding the underlying genetic condition, efforts aim to improve the diagnosis rate and reduce the age of diagnosis to ensure timely intervention. Collaboration between hospital pharmacy segments and drug stores facilitates access to essential medications for individuals with ASD.

Further, in addressing autism spectrum disorder, understanding anxiety and depressive symptoms among individuals, particularly within the children's age group, is paramount. Evaluating symptom severity and exploring underlying mechanisms are crucial for effective drug development and subsequent drug approvals. Consideration of geographic presence and tailored targeted therapies is essential, informed by genetic insights and novel therapies. Remote monitoring offers opportunities for enhanced care, considering factors such as ethnicity and advancements in biotechnology. Collaboration between hospitals and research centers is key in addressing the complexities of neurological disorders and improving social communication outcomes, especially given variations in birth rate.

Market Scope
Report Coverage	Details
Page number	157
Base year	2022
Historic period	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 7.2%
Market growth 2023-2027	USD 772.65 million
Market structure	Fragmented
YoY growth 2022-2023(%)	6.12
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 39%
Key countries	US, Canada, UK, Germany, and China
Competitive landscape	Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
Key companies profiled	AutismSTEP, Bristol Myers Squibb Co., CureMark LLC, F. Hoffmann La Roche Ltd., Fraser, Jazz Pharmaceuticals Plc, Johnson and Johnson Services Inc., Les Laboratoires Servier SAS, Neurim Pharmaceuticals Ltd., Novartis AG, Oryzon Genomics SA, Otsuka Holdings Co. Ltd., PaxMedica Inc., Q BioMed Inc., Scioto Biosciences Inc., Spectrum Pharmaceuticals Inc., Stalicla SA, Travere Therapeutics Inc., Yamo Pharmaceuticals LLC, and Zynerba Pharmaceuticals Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

View PDF Sample

What are the Key Data Covered in this Market Research Report?

CAGR of the market during the forecast period
Detailed information on factors that will drive the market growth and forecasting of the market between 2023 and 2027
Precise estimation of the market size and its contribution to the parent market
Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
Growth of the market across Europe, North America, APAC, South America, and Middle East and Africa
Thorough market growth analysis of the market’s competitive landscape and detailed information about companies
Comprehensive market analysis and report on the factors that will challenge the market research and growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements.

Get in touch

Table of Contents

1 Executive Summary

1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Distribution Channel
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Type
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition

3.2 Market segment analysis
- Exhibit 13: Market segments

3.3 Market size 2022

3.4 Market outlook: Forecast for 2022-2027
- Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
- Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

4.1 Global autism spectrum disorder therapeutics market 2017 - 2021
- Exhibit 18: Historic Market Size – Data Table on global autism spectrum disorder therapeutics market 2017 - 2021 ($ million)

4.2 Distribution Channel Segment Analysis 2017 - 2021
- Exhibit 19: Historic Market Size – Distribution Channel Segment 2017 - 2021 ($ million)

4.3 Type Segment Analysis 2017 - 2021
- Exhibit 20: Historic Market Size – Type Segment 2017 - 2021 ($ million)

4.4 Geography Segment Analysis 2017 - 2021
- Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)

4.5 Country Segment Analysis 2017 - 2021
- Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2022 and 2027

5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027

5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027

5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027

5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Distribution Channel

6.1 Market segments
- Exhibit 30: Chart on Distribution Channel - Market share 2022-2027 (%)
- Exhibit 31: Data Table on Distribution Channel - Market share 2022-2027 (%)

6.2 Comparison by Distribution Channel
- Exhibit 32: Chart on Comparison by Distribution Channel
- Exhibit 33: Data Table on Comparison by Distribution Channel

6.3 Retail pharmacy - Market size and forecast 2022-2027
- Exhibit 34: Chart on Retail pharmacy - Market size and forecast 2022-2027 ($ million)
- Exhibit 35: Data Table on Retail pharmacy - Market size and forecast 2022-2027 ($ million)
- Exhibit 36: Chart on Retail pharmacy - Year-over-year growth 2022-2027 (%)
- Exhibit 37: Data Table on Retail pharmacy - Year-over-year growth 2022-2027 (%)

6.4 Hospital pharmacy - Market size and forecast 2022-2027
- Exhibit 38: Chart on Hospital pharmacy - Market size and forecast 2022-2027 ($ million)
- Exhibit 39: Data Table on Hospital pharmacy - Market size and forecast 2022-2027 ($ million)
- Exhibit 40: Chart on Hospital pharmacy - Year-over-year growth 2022-2027 (%)
- Exhibit 41: Data Table on Hospital pharmacy - Year-over-year growth 2022-2027 (%)

6.5 Online pharmacy - Market size and forecast 2022-2027
- Exhibit 42: Chart on Online pharmacy - Market size and forecast 2022-2027 ($ million)
- Exhibit 43: Data Table on Online pharmacy - Market size and forecast 2022-2027 ($ million)
- Exhibit 44: Chart on Online pharmacy - Year-over-year growth 2022-2027 (%)
- Exhibit 45: Data Table on Online pharmacy - Year-over-year growth 2022-2027 (%)

6.6 Market opportunity by Distribution Channel
- Exhibit 46: Market opportunity by Distribution Channel ($ million)
- Exhibit 47: Data Table on Market opportunity by Distribution Channel ($ million)

7 Market Segmentation by Type

7.1 Market segments
- Exhibit 48: Chart on Type - Market share 2022-2027 (%)
- Exhibit 49: Data Table on Type - Market share 2022-2027 (%)

7.2 Comparison by Type
- Exhibit 50: Chart on Comparison by Type
- Exhibit 51: Data Table on Comparison by Type

7.3 Stimulants - Market size and forecast 2022-2027
- Exhibit 52: Chart on Stimulants - Market size and forecast 2022-2027 ($ million)
- Exhibit 53: Data Table on Stimulants - Market size and forecast 2022-2027 ($ million)
- Exhibit 54: Chart on Stimulants - Year-over-year growth 2022-2027 (%)
- Exhibit 55: Data Table on Stimulants - Year-over-year growth 2022-2027 (%)

7.4 Selective serotonin reuptake inhibitors - Market size and forecast 2022-2027
- Exhibit 56: Chart on Selective serotonin reuptake inhibitors - Market size and forecast 2022-2027 ($ million)
- Exhibit 57: Data Table on Selective serotonin reuptake inhibitors - Market size and forecast 2022-2027 ($ million)
- Exhibit 58: Chart on Selective serotonin reuptake inhibitors - Year-over-year growth 2022-2027 (%)
- Exhibit 59: Data Table on Selective serotonin reuptake inhibitors - Year-over-year growth 2022-2027 (%)

7.5 Antipsychotic drugs - Market size and forecast 2022-2027
- Exhibit 60: Chart on Antipsychotic drugs - Market size and forecast 2022-2027 ($ million)
- Exhibit 61: Data Table on Antipsychotic drugs - Market size and forecast 2022-2027 ($ million)
- Exhibit 62: Chart on Antipsychotic drugs - Year-over-year growth 2022-2027 (%)
- Exhibit 63: Data Table on Antipsychotic drugs - Year-over-year growth 2022-2027 (%)

7.6 Sleep medications - Market size and forecast 2022-2027
- Exhibit 64: Chart on Sleep medications - Market size and forecast 2022-2027 ($ million)
- Exhibit 65: Data Table on Sleep medications - Market size and forecast 2022-2027 ($ million)
- Exhibit 66: Chart on Sleep medications - Year-over-year growth 2022-2027 (%)
- Exhibit 67: Data Table on Sleep medications - Year-over-year growth 2022-2027 (%)

7.7 Others - Market size and forecast 2022-2027
- Exhibit 68: Chart on Others - Market size and forecast 2022-2027 ($ million)
- Exhibit 69: Data Table on Others - Market size and forecast 2022-2027 ($ million)
- Exhibit 70: Chart on Others - Year-over-year growth 2022-2027 (%)
- Exhibit 71: Data Table on Others - Year-over-year growth 2022-2027 (%)

7.8 Market opportunity by Type
- Exhibit 72: Market opportunity by Type ($ million)
- Exhibit 73: Data Table on Market opportunity by Type ($ million)

8 Customer Landscape

8.1 Customer landscape overview
- Exhibit 74: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
- Exhibit 75: Chart on Market share by geography 2022-2027 (%)
- Exhibit 76: Data Table on Market share by geography 2022-2027 (%)

9.2 Geographic comparison
- Exhibit 77: Chart on Geographic comparison
- Exhibit 78: Data Table on Geographic comparison

9.3 North America - Market size and forecast 2022-2027
- Exhibit 79: Chart on North America - Market size and forecast 2022-2027 ($ million)
- Exhibit 80: Data Table on North America - Market size and forecast 2022-2027 ($ million)
- Exhibit 81: Chart on North America - Year-over-year growth 2022-2027 (%)
- Exhibit 82: Data Table on North America - Year-over-year growth 2022-2027 (%)

9.4 Europe - Market size and forecast 2022-2027
- Exhibit 83: Chart on Europe - Market size and forecast 2022-2027 ($ million)
- Exhibit 84: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
- Exhibit 85: Chart on Europe - Year-over-year growth 2022-2027 (%)
- Exhibit 86: Data Table on Europe - Year-over-year growth 2022-2027 (%)

9.5 Asia - Market size and forecast 2022-2027
- Exhibit 87: Chart on Asia - Market size and forecast 2022-2027 ($ million)
- Exhibit 88: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
- Exhibit 89: Chart on Asia - Year-over-year growth 2022-2027 (%)
- Exhibit 90: Data Table on Asia - Year-over-year growth 2022-2027 (%)

9.6 Rest of World (ROW) - Market size and forecast 2022-2027
- Exhibit 91: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
- Exhibit 92: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
- Exhibit 93: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
- Exhibit 94: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)

9.7 US - Market size and forecast 2022-2027
- Exhibit 95: Chart on US - Market size and forecast 2022-2027 ($ million)
- Exhibit 96: Data Table on US - Market size and forecast 2022-2027 ($ million)
- Exhibit 97: Chart on US - Year-over-year growth 2022-2027 (%)
- Exhibit 98: Data Table on US - Year-over-year growth 2022-2027 (%)

9.8 UK - Market size and forecast 2022-2027
- Exhibit 99: Chart on UK - Market size and forecast 2022-2027 ($ million)
- Exhibit 100: Data Table on UK - Market size and forecast 2022-2027 ($ million)
- Exhibit 101: Chart on UK - Year-over-year growth 2022-2027 (%)
- Exhibit 102: Data Table on UK - Year-over-year growth 2022-2027 (%)

9.9 Germany - Market size and forecast 2022-2027
- Exhibit 103: Chart on Germany - Market size and forecast 2022-2027 ($ million)
- Exhibit 104: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
- Exhibit 105: Chart on Germany - Year-over-year growth 2022-2027 (%)
- Exhibit 106: Data Table on Germany - Year-over-year growth 2022-2027 (%)

9.10 Canada - Market size and forecast 2022-2027
- Exhibit 107: Chart on Canada - Market size and forecast 2022-2027 ($ million)
- Exhibit 108: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
- Exhibit 109: Chart on Canada - Year-over-year growth 2022-2027 (%)
- Exhibit 110: Data Table on Canada - Year-over-year growth 2022-2027 (%)

9.11 China - Market size and forecast 2022-2027
- Exhibit 111: Chart on China - Market size and forecast 2022-2027 ($ million)
- Exhibit 112: Data Table on China - Market size and forecast 2022-2027 ($ million)
- Exhibit 113: Chart on China - Year-over-year growth 2022-2027 (%)
- Exhibit 114: Data Table on China - Year-over-year growth 2022-2027 (%)

9.12 Market opportunity by geography
- Exhibit 115: Market opportunity by geography ($ million)
- Exhibit 116: Data Tables on Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

10.1 Market drivers

10.2 Market challenges

10.3 Impact of drivers and challenges
- Exhibit 117: Impact of drivers and challenges in 2022 and 2027

10.4 Market trends

11 Vendor Landscape

11.1 Overview

11.2 Vendor landscape
- Exhibit 118: Overview on Criticality of inputs and Factors of differentiation

11.3 Landscape disruption
- Exhibit 119: Overview on factors of disruption

11.4 Industry risks
- Exhibit 120: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
- Exhibit 121: Vendors covered

12.2 Market positioning of vendors
- Exhibit 122: Matrix on vendor position and classification

12.3 Bristol Myers Squibb Co.
- Exhibit 123: Bristol Myers Squibb Co. - Overview
- Exhibit 124: Bristol Myers Squibb Co. - Product / Service
- Exhibit 125: Bristol Myers Squibb Co. - Key news
- Exhibit 126: Bristol Myers Squibb Co. - Key offerings

12.4 CureMark LLC
- Exhibit 127: CureMark LLC - Overview
- Exhibit 128: CureMark LLC - Product / Service
- Exhibit 129: CureMark LLC - Key offerings

12.5 F. Hoffmann La Roche Ltd.
- Exhibit 130: F. Hoffmann La Roche Ltd. - Overview
- Exhibit 131: F. Hoffmann La Roche Ltd. - Business segments
- Exhibit 132: F. Hoffmann La Roche Ltd. - Key news
- Exhibit 133: F. Hoffmann La Roche Ltd. - Key offerings
- Exhibit 134: F. Hoffmann La Roche Ltd. - Segment focus

12.6 Jazz Pharmaceuticals Plc
- Exhibit 135: Jazz Pharmaceuticals Plc - Overview
- Exhibit 136: Jazz Pharmaceuticals Plc - Product / Service
- Exhibit 137: Jazz Pharmaceuticals Plc - Key news
- Exhibit 138: Jazz Pharmaceuticals Plc - Key offerings

12.7 Les Laboratoires Servier SAS
- Exhibit 139: Les Laboratoires Servier SAS - Overview
- Exhibit 140: Les Laboratoires Servier SAS - Business segments
- Exhibit 141: Les Laboratoires Servier SAS - Key offerings
- Exhibit 142: Les Laboratoires Servier SAS - Segment focus

12.8 Neurim Pharmaceuticals Ltd.
- Exhibit 143: Neurim Pharmaceuticals Ltd. - Overview
- Exhibit 144: Neurim Pharmaceuticals Ltd. - Product / Service
- Exhibit 145: Neurim Pharmaceuticals Ltd. - Key offerings

12.9 Novartis AG
- Exhibit 146: Novartis AG - Overview
- Exhibit 147: Novartis AG - Business segments
- Exhibit 148: Novartis AG - Key offerings
- Exhibit 149: Novartis AG - Segment focus

12.10 Oryzon Genomics SA
- Exhibit 150: Oryzon Genomics SA - Overview
- Exhibit 151: Oryzon Genomics SA - Product / Service
- Exhibit 152: Oryzon Genomics SA - Key offerings

12.11 Otsuka Holdings Co. Ltd.
- Exhibit 153: Otsuka Holdings Co. Ltd. - Overview
- Exhibit 154: Otsuka Holdings Co. Ltd. - Business segments
- Exhibit 155: Otsuka Holdings Co. Ltd. - Key offerings
- Exhibit 156: Otsuka Holdings Co. Ltd. - Segment focus

12.12 Q BioMed Inc.
- Exhibit 157: Q BioMed Inc. - Overview
- Exhibit 158: Q BioMed Inc. - Product / Service
- Exhibit 159: Q BioMed Inc. - Key offerings

12.13 Scioto Biosciences Inc.
- Exhibit 160: Scioto Biosciences Inc. - Overview
- Exhibit 161: Scioto Biosciences Inc. - Product / Service
- Exhibit 162: Scioto Biosciences Inc. - Key offerings

12.14 Spectrum Pharmaceuticals Inc.
- Exhibit 163: Spectrum Pharmaceuticals Inc. - Overview
- Exhibit 164: Spectrum Pharmaceuticals Inc. - Product / Service
- Exhibit 165: Spectrum Pharmaceuticals Inc. - Key offerings

12.15 Stalicla SA
- Exhibit 166: Stalicla SA - Overview
- Exhibit 167: Stalicla SA - Product / Service
- Exhibit 168: Stalicla SA - Key offerings

12.16 Yamo Pharmaceuticals LLC
- Exhibit 169: Yamo Pharmaceuticals LLC - Overview
- Exhibit 170: Yamo Pharmaceuticals LLC - Product / Service
- Exhibit 171: Yamo Pharmaceuticals LLC - Key offerings

12.17 Zynerba Pharmaceuticals Inc.
- Exhibit 172: Zynerba Pharmaceuticals Inc. - Overview
- Exhibit 173: Zynerba Pharmaceuticals Inc. - Product / Service
- Exhibit 174: Zynerba Pharmaceuticals Inc. - Key offerings

13 Appendix

13.1 Scope of the report

13.2 Inclusions and exclusions checklist
- Exhibit 175: Inclusions checklist
- Exhibit 176: Exclusions checklist

13.3 Currency conversion rates for US$
- Exhibit 177: Currency conversion rates for US$

13.4 Research methodology
- Exhibit 178: Research methodology
- Exhibit 179: Validation techniques employed for market sizing
- Exhibit 180: Information sources

13.5 List of abbreviations
- Exhibit 181: List of abbreviations

Methodology

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

Manufacturers and suppliers
Channel partners
Industry experts
Strategic decision makers

Secondary sources

Industry journals and periodicals
Government data
Financial reports of key industry players
Historical data
Press releases

DATA ANALYSIS

Data Synthesis

Collation of data
Estimation of key figures
Analysis of derived insights

Data Validation

Triangulation with data models
Reference against proprietary databases
Corroboration with industry experts

REPORT WRITING

Qualitative

Market drivers
Market challenges
Market trends
Five forces analysis

Quantitative

Market size and forecast
Market segmentation
Geographical insights
Competitive landscape

Purchase Report

PURCHASE FULL REPORT OF

autism spectrum disorder therapeutics market

Buy Report - Single User License 2500 USD

QUICK BUY

Key Questions Answered

What are the key global market and the regional market share?
What are the revenue-generating key market segments?
What are the key factors driving and challenging this market’s growth?
Who are the key market vendors and their growth strategies?
What are the latest trends influencing the growth of this market?
What are the variables influencing the market growth in the primary regions?
What are the factors influencing the growth of the parent market?

Why should you prefer Technavio's market insights report?

Off-the-shelf research reports
Reports can be tailored to meet the customer's needs
Trusted by more than 100 fortune 500 organizations
Information about the market's key drivers, trends, and challenges
Parent market analysis
Every week, 50,000 people visit our subscription platform
Detailed vendors report with competitive landscape
Covid-19 impact and recovery analysis
Data on revenue-generating market segments
Details on the market shares of various regions
Five-force market analysis